Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 14/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3832836 | 0.90 | RAB9A (0.47) | ROCK2RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL1482534 | 0.86 | UTS2R (0.53) | UTS2RROCK2ROCK1RAB9ANPC1 | |
| SCHEMBL4400931 | 0.80 | UTS2R (0.49) | UTS2RROCK2ROCK1RAB9AKMT2A | |
| SCHEMBL2474635 | 0.80 | UTS2R (0.50) | UTS2RRAB9ANPC1GAAALDH1A1 | |
| SCHEMBL1482676 | 0.78 | KMT2A (0.47) | ROCK2RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL2474633 | 0.75 | UTS2R (0.45) | UTS2RRAB9ANPC1GAAALDH1A1 | |
| SCHEMBL1482524 | 0.75 | UTS2R (0.45) | UTS2RROCK2ROCK1RAB9ANPC1 | |
| SCHEMBL2474154 | 0.75 | UTS2R (0.52) | UTS2RRAB9ANPC1KMT2AMEN1 | |
| SCHEMBL3835163 | 0.74 | HDAC1 (0.46) | UTS2RRAB9ANPC1KMT2AGAA | |
| SCHEMBL3835630 | 0.74 | NPC1 (0.50) | ROCK2RAB9ANPC1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288380-B2 | Thiophenediamine derivative having urea structure | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20120202808-A1 | NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-08-09 | — | — | US | disclosed |
| US-8198271-B2 | Thiophenediamine derivative having urea structure | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-06-12 | — | — | US | disclosed |
| US-8076332-B2 | N- (2-aminophenyl) benzamide derivative having urea structure | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-12-13 | — | — | US | disclosed |
| EP-2107052-B1 | NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE | SANTEN PHARMACEUTICAL CO LTD (JP) | 2011-10-12 | — | — | EP | disclosed |
| US-20110077244-A1 | NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-03-31 | — | — | US | disclosed |
| US-20090306077-A1 | NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-12-10 | — | — | US | disclosed |
| EP-2107052-A1 | NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE | Santen Pharmaceutical Co., Ltd (JP) | 2009-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202808-A1 | NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE | CBR1, NAT1, PRMT1 | UTS2R 195/4885ROCK2 3193/4885ROCK1 2339/4885 |
| US-20090306077-A1 | NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE | UACA, SLC14A1, ARG2 | UTS2R 11/4885ROCK2 499/4885ROCK1 700/4885 |
| US-20110077244-A1 | NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE | HNMT, HRH4, CHRM1 | UTS2R 10/4885ROCK2 4568/4885ROCK1 4291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.